Hashem Akhavan-Tafti, Ph.D.
The company founder and President, Hashem Akhavan-Tafti, Ph.D., was formerly the Vice President of Research for Beckman Coulter’s Immunoassay and Molecular Diagnostics Business Group. Hashem managed a multi-disciplinary team of research scientists in the discovery of innovative detection technologies for clinical diagnostics and life science research applications and holds more than 80 U.S. patents and more than 100 international patents related to chemiluminescent substrates used in medical diagnostic assays, and these inventions have had a profound impact on the field of chemiluminescence. Substrates he invented are used worldwide in automated systems for the chemiluminescent detection of alkaline phosphatase conjugates and in ultrasensitive assays in life-science research and human identity testing. His teams have refined methods for chemiluminescent enhancement, developed applications for DNA and protein detection using chemiluminescence, and developed methods for nucleic acid purification. Now leading the Ahuratec team, his newest patents in open-circuit electroluminescence are producing outstanding results in a broad range of fields.
Paul Glyer, CFA, eMBA
AhuraTech’s co-founder, Paul Glyer, has more than 30 years of experience in life sciences. Paul is an executive advisor to Waterstreet Healthcare. He is chairman of the board of Charityvest and chair of the finance committee of Axalbion Therapeutics. Until 2011 he was a member of the Office of the President for Beckman Coulter, helping drive revenue growth from <$1B to nearly $4B through strategic M&A activity. While he held a variety of roles throughout his career, his last position was leading the Investor Relations, Business Development and Corporate Strategy functions. He obtained an executive MBA from Claremont Graduate University and is a Chartered Financial Analyst.